Avidity Biosciences Inc (RNA) concluded trading on Thursday ata closing price of $45.49, with 3.1 million shares of worth about $141.19 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 236.71% during that period and on August 15, 2024 the price saw a gain of about 6.16%. Currently the company’s common shares owned by public are about 109.80M shares, out of which, 99.27M shares are available for trading.
Stock saw a price change of 8.65% in past 5 days and over the past one month there was a price change of 0.80%. Year-to-date (YTD), RNA shares are showing a performance of 402.65% which increased to 424.08% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.82 but also hit the highest price of $48.80 during that period. The average intraday trading volume for Avidity Biosciences Inc shares is 1.58 million. The stock is currently trading 2.10% above its 20-day simple moving average (SMA20), while that difference is up 11.93% for SMA50 and it goes to 103.59% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Avidity Biosciences Inc (NASDAQ: RNA) currently have 109.80M outstanding shares and institutions hold larger chunk of about 99.98% of that.
The stock has a current market capitalization of $4.99B and its 3Y-monthly beta is at 0.91. It has posted earnings per share of -$2.95 in the same period. It has Quick Ratio of 15.78 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RNA, volatility over the week remained 6.72% while standing at 6.26% over the month.
Stock’s fiscal year EPS is expected to drop by -1.53% while it is estimated to decrease by -4.25% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on May 03, 2024 offering a Buy rating for the stock and assigned a target price of $40 to it. Coverage by Cantor Fitzgerald stated Avidity Biosciences Inc (RNA) stock as an Overweight in their note to investors on March 14, 2024, suggesting a price target of $60 for the stock. On May 22, 2023, Evercore ISI Upgrade their recommendations, while on March 31, 2023, Evercore ISI Downgrade their ratings for the stock with a price target of $20. Stock get a Buy rating from Chardan Capital Markets on July 20, 2022.
